{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:39:32Z","timestamp":1761561572617},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T00:00:00Z","timestamp":1317686400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00210-011-0694-y","type":"journal-article","created":{"date-parts":[[2011,10,3]],"date-time":"2011-10-03T04:41:39Z","timestamp":1317616899000},"page":"1-3","source":"Crossref","is-referenced-by-count":5,"title":["Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits?"],"prefix":"10.1007","volume":"385","author":[{"given":"Peter","family":"Wood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,4]]},"reference":[{"key":"694_CR1","unstructured":"American Gastroenterological Association (2011) The burden of gastrointestinal diseases. American Gastroenterological Association, 2011, Bethesda, MD. Available at http:\/\/www.gastro.org\/education-meetings\/online-education\/niddk-burden-of-digestive-diseases-in-the-united-states-educational-slides (link to \u201ccosts of digestive diseases\u201d). Accessed 7 Sep 2011)"},{"key":"694_CR2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00001721-200404000-00006","volume":"15","author":"E Bermejo","year":"2004","unstructured":"Bermejo E, Alberto MF, Meschengieser SS, Lazzari MA (2004) Assessment of platelet activation in myeloproliferative disorders with complementary techniques. Blood Coagul Fibrinolysis 15:235\u2013240","journal-title":"Blood Coagul Fibrinolysis"},{"key":"694_CR3","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa0800670","volume":"358","author":"M Camilleri","year":"2008","unstructured":"Camilleri M, Kerstens R, Rykx A, Vandeplassche L (2008) A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358:2344\u20132354","journal-title":"N Engl J Med"},{"key":"694_CR4","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1111\/j.1538-7836.2007.02655.x","volume":"5","author":"G Gaetano de","year":"2007","unstructured":"de Gaetano G, Cerletti C (2007) Platelet function, antiplatelet therapy and clinical outcomes: to test or not to test? J Thromb Haemost 5:1835\u20131838","journal-title":"J Thromb Haemost"},{"issue":"22","key":"694_CR5","first-page":"1402","volume":"2010","author":"P Enck","year":"2010","unstructured":"Enck P, Junne F, Klosterhalfen S, Zipfel S, Martens U (2010) Therapy options in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2010(22):1402\u20131411","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"694_CR6","unstructured":"Food and Drug Administration (2011) FDA announces discontinued marketing of GI drug, Zelnorm, for safety reasons. Food and Drug Administration, Bethesda (MD). Available at http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2007\/ucm108879.htm . Accessed 4 July 2011"},{"key":"694_CR7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0016-5085(98)70203-3","volume":"115","author":"JR Grider","year":"1998","unstructured":"Grider JR, Foxx-Orenstein AE, Jin JG (1998) 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 115:370\u2013380","journal-title":"Gastroenterology"},{"key":"694_CR8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/MJT.0b013e3181b63f21","volume":"17","author":"VL Serebruany","year":"2010","unstructured":"Serebruany VL, El Mouelhi M, Pfannkuche H, Rose K, Marro M, Angiolillo D (2010) Investigations on 5-HT4 receptor expression and effects of tegaserod on human platelet aggregation in vitro. Am J Ther 17:543\u2013552","journal-title":"Am J Ther"},{"key":"694_CR9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2982.2004.00550.x","volume":"16","author":"JF Johanson","year":"2004","unstructured":"Johanson JF (2004) Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies. Neurogastroenterol Motil 16:701\u2013711","journal-title":"Neurogastroenterol Motil"},{"key":"694_CR10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1160\/TH10-07-0485","volume":"104","author":"SF Mause","year":"2010","unstructured":"Mause SF, Weber C, Sampol J, Dignat-George F (2010) New horizons in vascular biology and thrombosis: highlights from EMVBM 2009. Thromb Haemost 104:421\u2013423","journal-title":"Thromb Haemost"},{"key":"694_CR11","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1111\/j.1572-0241.2002.05986.x","volume":"97","author":"J Morganroth","year":"2002","unstructured":"Morganroth J, Ruegg PC, Dunger-Baldauf C, Appel-Dingemanse S, Bliesath H, Lefkowitz M (2002) Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol 97:2321\u20132327","journal-title":"Am J Gastroenterol"},{"key":"694_CR12","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1046\/j.1365-2036.2001.01094.x","volume":"15","author":"SA Muller-Lissner","year":"2001","unstructured":"Muller-Lissner SA, Fumagalli I, Bardhan KD et al (2001) Tegaserod, a 5-HT4receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 15:1655\u20131666","journal-title":"Aliment Pharmacol Ther"},{"key":"694_CR13","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1046\/j.1365-2036.2002.01372.x","volume":"16","author":"J Novick","year":"2002","unstructured":"Novick J, Miner P, Krause R et al (2002) A randomized, double blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 16:1877\u20131888","journal-title":"Aliment Pharmacol Ther"},{"key":"694_CR14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1161\/CIRCINTERVENTIONS.109.928861","volume":"3","author":"J Price","year":"2010","unstructured":"Price J (2010) The evidence base for platelet function testing in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 3:277\u2013283","journal-title":"Circ Cardiovasc Interv"},{"key":"694_CR15","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s10620-011-1702-2","volume":"56","author":"R Schey","year":"2011","unstructured":"Schey R, Rao SSC (2011) Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig Dis Sci 56:1619\u20131625","journal-title":"Dig Dis Sci"},{"issue":"Suppl. 7","key":"694_CR16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2036.2004.02182.x","volume":"20","author":"P Schoenfeld","year":"2004","unstructured":"Schoenfeld P (2004) Review article: the safety profile of tegaserod. Aliment Pharmacol Ther 20(suppl 7):25\u201330","journal-title":"Aliment Pharmacol Ther"},{"key":"694_CR17","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1046\/j.1365-2036.2002.01347.x","volume":"16","author":"G Tougas","year":"2002","unstructured":"Tougas G, Snape WJ, Otten MH et al (2002) Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 16:1701\u20131708","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-011-0694-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-011-0694-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-011-0694-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T12:14:56Z","timestamp":1558613696000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-011-0694-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,4]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["694"],"URL":"https:\/\/doi.org\/10.1007\/s00210-011-0694-y","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,4]]}}}